Delivery Order SPE2DB20D1109-SPE2DB25FP78A
- Not listed
- The Defense Logistics Agency awarded a $5,383.18 delivery order to AmerisourceBergen Drug Corp for 60-count tablets of Xifaxan 550 mg, an antibiotic medication commonly used to treat traveler's diarrhea and hepatic encephalopathy. The contract employs firm fixed pricing with a delivery deadline of September 16, 2025, and was awarded on a competitive basis without any set-aside designation. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,968.01 to AmerisourceBergen Drug Corp for 60-count tablets of Xifaxan 550 mg, an antibiotic medication used to treat traveler's diarrhea and certain gastrointestinal conditions. This competitively awarded, firm fixed-price delivery order was issued on September 3, 2025, with an ultimate completion date of September 4, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $4,590.98 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 tablets of Xifaxan 550 mg, an antibiotic medication commonly used to treat traveler's diarrhea and hepatic encephalopathy. The contract, awarded on September 12, 2025, with an ultimate completion date of September 15, 2025, was competitively awarded with no set-aside designation. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $7,595.77 to AmerisourceBergen Drug Corp for 60-count tablets of Xifaxan 550 mg, an antibiotic medication commonly used to treat traveler's diarrhea and hepatic encephalopathy. The contract was competitively awarded without set-aside restrictions on August 15, 2025, with an ultimate completion date of August 18, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $90,183.55 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60-count tablets of Xifaxan 550 mg, an antibiotic medication commonly used to treat traveler's diarrhea and hepatic encephalopathy. This competitively awarded, non-set-aside delivery order has an ultimate completion date of August 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child order...
- The Defense Logistics Agency awarded a $36,970.57 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60-tablet supplies of Xifaxan 550 mg, an antibiotic medication used to treat traveler's diarrhea and irritable bowel syndrome. The contract was competitively awarded without set-aside designation and is scheduled for completion by July 21, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,249.80 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on September 12, 2025, with an ultimate completion date of September 15, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The delivery order represents a discrete purchase under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $11,106.33 to AmerisourceBergen Drug Corp for 60-count tablets of Xifaxan 550 mg, an antibiotic used to treat traveler's diarrhea and certain gastrointestinal conditions. This firm fixed price contract, awarded on August 18, 2025, represents a non-competitive set-aside delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a $19,464.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60-count bottles of Xifaxan 550 mg tablets, an antibiotic medication used to treat traveler's diarrhea and other gastrointestinal conditions. The contract is non-compete and was awarded on May 2, 2025, with an ultimate completion date of May 5, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,344.55 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on June 4, 2025, with a completion date of June 5, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999.9...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP78ADelivery Order
The Defense Logistics Agency (DLA) awarded a $1,050.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 tablets of Xifaxan 550 mg, an antibiotic medication commonly prescribed for traveler's diarrhea and hepatic encephalopathy. The contract was competitively awarded without a set-aside designation and is set for completion by September 18, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal military and veteran healthcare systems through the DLA Medical Supply Chain. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The prime IDC functions as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a broad range of brand-name and generic medications, vaccines, and medical supplies to support military healthcare programs worldwide. The company's track record demonstrates consistent capability to fulfill federal medical procurement requirements through open competition, with prior awards ranging from small-value transactions to substantial orders exceeding $45,000.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 9/17/25 |